Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Abbott Laboratories
  • Aethlon Medical Inc.
  • Allscripts Healthcare Solutions, Inc.
  • BioLife Solutions Inc.
  • Biomerica Inc.
  • Cryoport Inc.
  • CytoSorbents Corp.
  • FluoroPharma Medical Inc.
  • HealthTronics Inc.
  • iCAD, Inc.
  • Interleukin Genetics Inc.
  • Mela Sciences Inc.
  • Merck & Co. Inc.
  • OptimizeRx Corp.
  • Pfizer Inc.
  • SANUWAVE Health, Inc.
  • Verisante Technology Inc.
  • VolitionRx Ltd.
  • Zecotek Photonics Inc.

Brian Marckx

Zacks Small-Cap Research

Image: Brian Marckx

Brian Marckx is the senior medical device/diagnostics analyst with Zacks Investment Research, He covers small- and micro-cap medical device and diagnostic companies with a focus on development-stage companies with novel and emerging technologies, as well as already established names still flying under the radar. Prior to joining Zacks, Marckx worked as a high-yield bond analyst on Wachovia Securities' institutional trading desks, where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Marckx has been quoted in The Wall Street Journal, Barron's, Bloomberg Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. He graduated with a bachelor's degree in finance from St. John Fisher College, and received his master's degree in business administration from Wake Forest University. Marckx is also a Chartered Financial Analyst.




Recent Interviews

Micro-Cap Medtech with Explosive Upside Potential: Brian Marckx (12/19/13) Combine the complexity of genomic testing with the high risk inherent in micro-cap stocks, and you have investment opportunities that require exceptional diligence. The reward for understanding the value proposition of budding companies? The payoff can be enormous. In this interview with The Life Sciences Report, Senior Medical Device Analyst Brian Marckx of Zacks Investment Research has selected eight micro-cap names that could return triples, quads and more for investors willing to do their homework.

Eight Small-Cap Medtechs with Big Prospects: Brian Marckx (8/7/13) Small-cap medical technology has long been regarded as the ugly duckling of biotech. . .but think again. Brian Marckx of Zacks Small-Cap Research believes that the real gems of the medtech space complementŚand can even outshineŚsexier drug and surgical therapies. In this interview with The Life Sciences Report, Marckx makes a strong case for eight small- and micro-cap names that could bring home huge returns for investors.

Recent Quotes

"VRS closed a private placement for gross proceeds of $481K." (4/10/14) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"BFLS' contract manufacturing business is expected to provide a source of near-term revenue and cash flow." (3/31/14) BioLife Solutions Inc. - Brian Marckx, Zacks Investment Research Moreá>

"BLFS' revenue has broken records, continually increasing over the last 13 of 14 quarters." (2/14/14) BioLife Solutions Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"We are maintaining our Outperform rating on BLFS." (1/29/14) BioLife Solutions Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"BLFS has its own proprietary biopreservation media, and it has been doing very well." (12/19/13) BioLife Solutions Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>

"VRS's Aura device for noninvasive skin cancer detection is superior in accuracy and much faster." (12/19/13) Verisante Technology Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>

"VRS' Aura continues to be recognized as one of the leading novel medical technologies." (12/2/13) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"We anticipate a CE mark for VNRX's NuQ technology by next year." (11/25/13) VolitionRx Ltd. - Brian Marckx, Zacks Small-Cap Research Moreá>

more comments

"We are increasing our price target for BLFS and maintaining our Outperform rating." (11/14/13) BioLife Solutions Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"VNRX's new distribution agreement will significantly boost its product reach." (11/5/13) VolitionRx Ltd. - Brian Marckx, Zacks Small-Cap Research Moreá>

"VRS' Q2/13 gross margin was a significant improvement over Q1/13's." (9/3/13) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"BLFS' Q2/13 revenue set another all-time record." (8/12/13) BioLife Solutions Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"BLFS, which expects to benefit from the emerging field of regenerative medicine, set a new revenue record for the ninth straight quarter." (8/8/13) BioLife Solutions Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>

"VRS makes a device called the Aura for the detection of skin cancer, which is a virtually untapped detection device market." (8/8/13) Verisante Technology Inc. - The Life Sciences Report Interview with Brian Marckx Moreá>

"VNRX's 10,800-patient study in colorectal cancer could be a big deal." (8/8/13) VolitionRx Ltd. - The Life Sciences Report Interview with Brian Marckx Moreá>

"We are maintaining our Outperform rating on VNRX." (7/30/13) VolitionRx Ltd. - Brian Marckx, Zacks Small-Cap Research Moreá>

"VRS' recent string of various award wins and recognitions for Aura are important votes of confidence." (5/31/13) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

"BLFS' Q1/13 gross margin was very strong at 52%." (5/17/13) BioLife Solutions Inc. - Brian Marckx, Seeking Alpha Moreá>

"VRS' Aura continues to be recognized as one of the leading novel medical technologies throughout the world." (12/3/12) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.